Related Experiment Video
Updated: Jun 19, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer
1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. cvdang@jhmi.edu
Abstract:
In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.
Insights
The enzyme EglN2 promotes breast cancer growth by increasing Cyclin D1 levels. Inhibiting EglN2 may offer a new therapeutic strategy for breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The study investigates the role of EglN2, an iron-dependent 2-oxoglutarate dioxygenase, in breast cancer.
- EglN2 is identified as a key regulator of Cyclin D1 levels.
Discussion:
- Zhang et al. demonstrate that EglN2 directly influences Cyclin D1 expression.
- This induction of Cyclin D1 by EglN2 contributes to the progression of breast tumorigenesis.
Key Insights:
- Loss-of-function studies reveal EglN2's critical role in promoting breast cancer.
- EglN2's mechanism involves the upregulation of Cyclin D1, a known driver of cell proliferation.
Outlook:
- Targeting EglN2 presents a promising new avenue for breast cancer therapy.
- Development of drug-like molecules that inhibit EglN2 could lead to novel anti-cancer therapeutics.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle
Positive Regulator Molecules

